Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Special lenses could slow worsening eyesight in kids

NCT ID NCT05888792

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of spectacle lens (DG2) designed to slow down nearsightedness (myopia) in children whose vision is getting worse quickly. 118 children aged 4–13 will wear these lenses for 4 years. Researchers will measure changes in their eye prescription and eye length every 6 months to see if the lenses effectively control myopia progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Defocus Incorporated Multiple Segments spectacle lens (DG2)
What this could lead to
If successful, these lenses could offer a simple, non-invasive way to slow worsening nearsightedness in children, potentially reducing the risk of serious eye diseases later in life.
What could go wrong
This is a relatively small study (118 children) and results may not apply to all kids. The lenses only slow progression, not stop or reverse it, and long-term benefits beyond 4 years are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 118 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * SER: -0.75D or below in both eyes * Documented history of fast progressing myopia, either in SER or AL * SER progression: 0.50D/year or more * AL elongation: 0.27mm/year or more * For children aged 4-6 years without past prescription forms, * 4-5 years old: myopia of -0.75D or below in both eyes * 6 years old: myopia of -1.25D or below in at least one eye, with the other eye -0.75D or below * Best-corrected visual acuity (VA) in both eyes: * 4 - 6 years old: 0.20 logMAR (or its equivalent) or better * 7-12 years old: 0.00 logMAR (or its equivalent) or better * Acceptance of random group allocation and the masked study design * Anisometropia of 1.50 D or less * Astigmatism of 2.00 D or less Exclusion Criteria: * Strabismus and binocular vision abnormalities * Ocular and systemic abnormalities * Prior experience of myopia control

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • School of Optometry, The Hong Kong Polytechnic University

    Hung Hom, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.